Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-031 Extension in Duchenne Muscular Dystrophy
NCT01239758Phase 2Terminated
- Start
- Oct 2010
- Primary completion
- May 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of ramatercept in Duchenne muscular dystrophy (DMD) (3 cohorts). Primary endpoints: Number of patients with adverse events at 24 weeks and Change in laboratory parameters and vital signs at 24 weeks. Started Oct 2010; status: terminated.
02
Drugs
ramatercept
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT01239758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01239758.